Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Salubris Pharmaceuticals Co., Ltd.
  6. News
  7. Summary
    002294   CNE100000FW8

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

(002294)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.

07/25/2021 EDT

The Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. has authorized a buyback plan on July 25, 2021.


© S&P Capital IQ 2021
All news about SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
10/07Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
CI
09/05Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.
CI
08/23Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
DJ
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Rights to Combination Therapy Candidate for Ly..
MT
08/23Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year ..
CI
08/06SKILLFUL CRAFTSMAN EDUCATION TECHNOL : Names Dawei Chen as Chief Financial Officer
MT
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 200 mil..
CI
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
CI
07/25SHENZHEN SALUBRIS PHARMACEUTICALS CO : 002294) intends to launch an Equity Buyback Plan.
CI
07/02Salubris Biotechnology Co., Ltd. announced that it expects to receive CNY 263.8 million..
CI
More news
Financials
Sales 2021 2 801 M 439 M 439 M
Net income 2021 684 M 107 M 107 M
Net cash 2021 627 M 98,2 M 98,2 M
P/E ratio 2021 40,9x
Yield 2021 0,99%
Capitalization 29 855 M 4 676 M 4 677 M
EV / Sales 2021 10,4x
EV / Sales 2022 8,69x
Nbr of Employees 3 448
Free-Float 35,3%
Chart SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Duration : Period :
Shenzhen Salubris Pharmaceuticals Co., Ltd. Technical Analysis Chart | 002294 | CNE100000FW8 | MarketScreener
Technical analysis trends SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 26,78 CNY
Average target price 26,50 CNY
Spread / Average Target -1,05%
EPS Revisions
Managers and Directors
Sing Ye General Manager & Director
Jun Liu Chief Financial Officer
Cheng Hai Ye Chairman
Ai Zhen Li Chairman-Supervisory Board
Ji Tang Member-Supervisory Board & Administrative Director